Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Epigenetix Closes $21M Financing Round

NEW YORK (GenomeWeb) – Epigenetics sequencing firm Cambridge Epigenetix announced today the close of a $21 million Series B financing round.

The round was led by GV, formerly known as Google Ventures, and included Sequoia Capital, New Science Ventures, Syncona Partners, and the University of Cambridge.

Cambridge Epigenetix was founded in 2012 as a spinout of Shankar Balasubramanian's laboratory at the University of Cambridge around an epigenetic sequencing technique called oxidative bisulfite sequencing, which is used for the quantitative, single-base resolution sequencing of 5-hydroxymethylcytosine and 5-methycytosine. 

The company raised $5.5 million in a Series A round in late 2014.